The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Glycine and a Glycine Dehydrogenase (GLDC) SNP as Citalopram/Escitalopram Response Biomarkers in Depression: Pharmacometabolomics-Informed Pharmacogenomics
Open accessAbstract
Major depressive disorder (MDD) is a common psychiatric disease. Selective serotonin reuptake inhibitors (SSRIs) are an important class of drugs used in the treatment of MDD. However, many patients do not respond adequately to SSRI therapy. We used a pharmacometabolomics-informed pharmacogenomic research strategy to identify citalopram/escitalopram treatment outcome biomarkers. Metabolomic assay of plasma samples from 20 escitalopram remitters and 20 nonremitters showed that glycine was negatively associated with treatment outcome (P = 0.0054). This observation was pursued by genotyping tag single-nucleotide polymorphisms (SNPs) for genes encoding glycine synthesis and degradation enzymes, using 529 DNA samples from SSRI-treated MDD patients. The rs10975641 SNP in the glycine dehydrogenase (GLDC) gene was associated with treatment outcome phenotypes. Genotyping for rs10975641 was carried out in 1,245 MDD patients in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, and its presence was significant (P = 0.02) in DNA taken from these patients. These results highlight a possible role for glycine in SSRI response and illustrate the use of pharmacometabolomics to "inform" pharmacogenomics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692 · cited 1×
“Q-values were also obtained to control for the false discovery rate (37).”
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 3×
“Inclusion and exclusion criteria were similar to those of the STAR*D study (15).”
InfluentialRush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder
Kato, M., & Serretti, A. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.116 · Cited by 450
Correlation between plasma levels of glutamate, alanine and serine with severity of depression
Mitani, H., Shirayama, Y., Yamada, T., Maeda, K., Ashby, C. R., & Kawahara, R. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.03.036 · Cited by 332
Thase, M. E., Haight, B. R., Richard, N., Rockett, C. B., Mitton, M., Modell, J. G., VanMeter, S., Harriett, A. E., & Wang, Y. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0803 · Cited by 304
Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R. A., Lee, D., Yao, J. K., Doraiswamy, P. M., & Krishnan, K. R. R. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002000 · Cited by 262
Altamura, C., Maes, M., Dai, J., & Meltzer, H. Y. (1995) · European Neuropsychopharmacology · doi:10.1016/0924-977x(95)00033-l · Cited by 193
(1998) · doi:10.1177/0148607198022006393 · Cited by 73
Cited by
Metabolomics: beyond biomarkers and towards mechanisms
Johnson, C. H., Ivanisevic, J., & Siuzdak, G. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.25 · Cited by 2,829
Cleare, A., Pariante, C., Young, A., Anderson, I., Christmas, D., Cowen, P., Dickens, C., Ferrier, I., Geddes, J., Gilbody, S., et al. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115581093 · Cited by 759
Metabolomics enables precision medicine: “A White Paper, Community Perspective”
for “Precision Medicine and Pharmacometabolomics Task Group”-Metabolomics Society Initiative, Beger, R. D., Dunn, W., Schmidt, M. A., Gross, S. S., Kirwan, J. A., Cascante, M., Brennan, L., Wishart, D. S., Oresic, M., et al. (2016) · Metabolomics · doi:10.1007/s11306-016-1094-6 · Cited by 592
Self-citationHan, X., Rozen, S., Boyle, S. H., Hellegers, C., Cheng, H., Burke, J. R., Welsh-Bohmer, K. A., Doraiswamy, P. M., & Kaddurah-Daouk, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021643 · Cited by 429
Self-citationSavignac, H. M., Kiely, B., Dinan, T. G., & Cryan, J. F. (2014) · Neurogastroenterology & Motility · doi:10.1111/nmo.12427 · Cited by 418
Systems Pharmacology: Network Analysis to Identify Multiscale Mechanisms of Drug Action
Zhao, S., & Iyengar, R. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134520 · Cited by 358
Challenges and opportunities of metabolomics
Johnson, C. H., & Gonzalez, F. J. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24002 · Cited by 311
Xenobiotic Metabolomics: Major Impact on the Metabolome
Johnson, C. H., Patterson, A. D., Idle, J. R., & Gonzalez, F. J. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134748 · Cited by 269
Metabolomics in the study of kidney diseases
Weiss, R. H., & Kim, K. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.152 · Cited by 264
Gadad, B. S., Jha, M. K., Czysz, A., Furman, J. L., Mayes, T. L., Emslie, M. P., & Trivedi, M. H. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.07.001 · Cited by 205
Enteric Microbiome Metabolites Correlate with Response to Simvastatin Treatment
Kaddurah-Daouk, R., Baillie, R. A., Zhu, H., Zeng, Z.-B., Wiest, M. M., Nguyen, U. T., Wojnoonski, K., Watkins, S. M., Trupp, M., & Krauss, R. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025482 · Cited by 193
Self-citationA randomized add-on trial of high-dose d-cycloserine for treatment-resistant depression
Heresco-Levy, U., Gelfin, G., Bloch, B., Levin, R., Edelman, S., Javitt, D. C., & Kremer, I. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000910 · Cited by 177
“Treatment refractory depression may be aetiologically distinct from other depression forms andmay specifically involve disturbances in glycine metabolism (Ji et al. 2011).”
BackgroundMeyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Blood biomarkers and treatment response in major depression
Mora, C., Zonca, V., Riva, M. A., & Cattaneo, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470927 · Cited by 107
Impaired Plasmalogens in Patients with Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R., Zhu, H., K. Yao, J., Nimgaonkar, V. L., Buckley, P. F., Keshavan, M. S., Georgiades, A., & Nasrallah, H. A. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.019 · Cited by 89
“Sophisticated metabolomic analytical platforms and informatics tools enablemapping of pathways implicated in disease and in response to therapy (Kristal et al., 2007; Kaddurah-Daouk et al., 2008; Kaddurah-Daouk and Krishnan, 2009; Ji et al., 2011; Kaddurah-Daouk et al., 2011).”
BackgroundSelf-citationMoaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M. P., Garcia, A., Bernier, M., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3669-0 · Cited by 86
“…relationship to the pharmacological mechanism of the therapeutic agent, as plasma levels of glycine have been identified as a biomarker of response for treatment with the SSRIs citalopram and escitalopram (Ji et al. 2011), but were not identified in the initial metabolomics study of KET response.”
BackgroundResultInfluentialCerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile
Kaddurah-Daouk, R., Yuan, P., Boyle, S. H., Matson, W., Wang, Z., Zeng, Z. B., Zhu, H., Dougherty, G. G., Yao, J. K., Chen, G., et al. (2012) · Scientific Reports · doi:10.1038/srep00667 · Cited by 76
Self-citationPharmacometabonomics and personalized medicine
Everett, J. R., Loo, R. L., & Pullen, F. S. (2013) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/0004563213497929 · Cited by 75
Villaseñor, A., Ramamoorthy, A., Silva dos Santos, M., Lorenzo, M. P., Laje, G., Zarate, C., Barbas, C., & Wainer, I. W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12494 · Cited by 71
Metadata
- Authors
- Ji, Y., Hebbring, S., Zhu, H., Jenkins, G. D., Biernacka, J., Snyder, K., Drews, M., Fiehn, O., Zeng, Z., Schaid, D., Mrazek, D. A., Kaddurah-Daouk, R., & Weinshilboum, R. M.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2010-11-24
- Volume
- 89
- Issue
- 1
- Pages
- 97-104
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2113638381
- Cited by
- 160
- References
- 10
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.